UBS Group’s Hologic HOLX Stock Holding History

UBS Group’s Portfolio HOLX Stock Details HOLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,400	Closed	-$769K	–	10798
2025 Q3	$769K	Buy	+11,400	New	+$757K	﹤0.01%	5769
2024 Q1	–	Sell	-40,000	Closed	-$2.86M	–	9618
2023 Q4	$2.86M	Buy	+40,000	New	+$2.79M	﹤0.01%	3427
2022 Q3	–	Sell	-214,000	Closed	-$14.8M	–	10583
2022 Q2	$14.8M	Hold	214,000	–	–	0.01%	1530
2022 Q1	$16.4M	Buy	+214,000	New	+$15.4M	0.01%	1581
2017 Q3	–	Sell	-40,000	Closed	-$1.81M	–	7841
2017 Q2	$1.81M	Buy	+40,000	New	+$1.77M	﹤0.01%	3107
2015 Q2	–	Sell	-52,500	Closed	-$1.73M	–	8643
2015 Q1	$1.73M	Buy	52,500 +1,000	+2%	+$30.7K	﹤0.01%	3065
2014 Q4	$1.38M	Buy	+51,500	New	+$1.33M	﹤0.01%	3286

Other funds holding HOLX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group's HOLX Position: Q2 2026 in Review

UBS Group sold out of Hologic (HOLX) in Q2 2026, closing a stake of 5,089,745 shares — an estimated $385M sold.

UBS Group first reported a position in HOLX in Q4 2014 and held it in 46 quarters. The position peaked at $385M in Q1 2026. 3 funds tracked by Wall St. Rank hold HOLX as of Q2 2026.

UBS Group reported no remaining Hologic position as of Q2 2026 after selling out during the quarter.
UBS Group sold 5,089,745 Hologic shares in Q2 2026, an estimated $385M.
UBS Group first reported a position in Hologic in Q4 2014 and held it in 46 quarters.
UBS Group's Hologic position peaked at $385M in Q1 2026.
3 funds tracked by Wall St. Rank held Hologic as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.